NASDAQ: LBPH - Longboard Pharmaceuticals, Inc.

六个月盈利: +79.96%
股息率: 0.00%
部门: Healthcare

促销时间表 Longboard Pharmaceuticals, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc.

更多详情
to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2021-03-12
ISIN US54300N1037
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.longboardpharma.com
Цена ао 59.98
每日价格变化: 0% (59.98)
每周价格变化: 0% (59.98)
每月价格变化: 0% (59.98)
3个月内价格变化: 0% (59.98)
六个月内的价格变化: +79.96% (33.33)
每年价格变化: +177.69% (21.6)
3年内价格变化: +1 012.8% (5.39)
年初以来价格变化: 0% (59.98)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 3.44 5
P/E 0 0
EV/EBITDA -2.24 0
全部的: 3.13

效率

姓名 意义 年级
ROA, % -107.35 0
ROE, % -132.99 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0084 10
全部的: 8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % 294.13 10
盈利能力 EPS, % 181.33 10
全部的: 8
更多详情

机构 体积 分享, %
Cormorant Asset Management, LP 2353141 7
FMR, LLC 1649503 4.91
Price (T.Rowe) Associates Inc 1626982 4.84
Farallon Capital Management Llc 1560500 4.64
Polar Capital Holdings PLC 1000000 2.98
Ikarian Capital, LLC 979462 2.91
Integral Health Asset Management, LLC 900000 2.68
Blackrock Inc. 869879 2.59
Point72 Asset Management, L.P. 825000 2.45
Vanguard Group Inc 786433 2.34

ETF分享, %本年盈利能力, %股息, %
SPDR S&P Pharmaceuticals ETF 2.34795 29.8 1.29889
iShares Neuroscience and Healthcare ETF 2.11526 19.72 0.03
Virtus LifeSci Biotech Clinical Trials ETF 1.3448 63.04 0.33
Direxion Daily Pharmaceutical & Medical Bull 3X Shares 1.2465 86.72 1.2989
iShares Micro-Cap ETF 0.27803 17.09 1.54048
Vanguard U.S. Momentum Factor ETF 0.18 30.05 1.05834
Nuveen ESG Small-Cap ETF 0.09807 13.91 1.41019
Vanguard Russell 2000 Growth ETF 0.09 23.05 0.60264
iShares Russell 2000 Growth ETF 0.08101 38.04 0.6026
iShares ESG Aware MSCI USA Small-Cap ETF 0.04743 18.09 1.49366
Vanguard Russell 2000 ETF 0.04 17.16 1.48801
ProShares UltraPro Russell2000 0.02367 89.82 1.47873
iShares Morningstar Small-Cap Value ETF 0.02069 201.65 2.50476
iShares Morningstar Small Cap Value ETF 0.02069 26.7 2.50476
iShares Morningstar Small-Cap ETF 0.01851 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.01851 391.25 1.60498
Avantis U.S Small Cap Equity ETF 0.01814 27.77 1.68271
iShares Morningstar Small-Cap Growth ETF 0.01676 587.89 0.72598
iShares Morningstar Small-Cap Growth ETF 0.01676 33.63 0.72598
Fidelity MSCI Health Care Index ETF 0.01532 3 1.46057
ProShares Hedge Replication ETF 0.0058 5.92 1.47892
Humankind US Stock ETF 0.00353 18.81 1.99919
iShares Russell 3000 ETF 0.00126 24.83 1.43482
Avantis U.S. Equity ETF 0.00066 23.04 1.59151
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.3274.121.33



导师 职称 支付 出生年份
Mr. Kevin R. Lind President, CEO, Secretary & Director 1.07M 1976 (49 年)
Ms. Brandi L. Roberts CPA, M.B.A. Executive VP & CFO 662.65k 1974 (51 年)
Dr. Randall E. Kaye M.D. Executive VP & Chief Medical Officer 717.95k 1962 (63 年)
Mr. Chadwick J. Orevillo MPH Executive VP & Head of Operations N/A
Mr. Steven W. Spector J.D. Executive VP, Head of Business Development & General Counsel N/A 1965 (60 年)
Dr. Anne M. Danks Ph.D. VP & Head of Nonclinical Research & Development N/A
Mr. Gus Cardenas VP & Head of Quality Assurance N/A
Dr. Marco Peters Ph.D. VP & Head of Translational Science N/A
Dr. Dewey McLin Ph.D. VP & Head of Medical Affairs N/A
Ms. Megan E. Knight VP & Head of Investor Relations

地址: United States, La Jolla. CA, 4275 Executive Square - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.longboardpharma.com